(Q36349691)

13 August 2017

1 reference

title

Aerosolised antibiotics: a critical appraisal of their use. (English)

1 reference

13 August 2017

0 references

Jennifer K Hagerman

1

1 reference

13 August 2017

Kim E Hancock

series ordinal

2

1 reference

13 August 2017

Michael E Klepser

series ordinal

3

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

Expert Opinion on Drug Delivery

13 August 2017

published in

1 reference

13 August 2017

volume

3

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

71-86

1 reference

The role of nebulized antibiotics in treating serious respiratory infections

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Treatment With tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Quantitative deposition of aerosolized gentamicin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Aerosol deposition considerations in inhalation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Evaluation of jet nebulisers for use with gentamicin solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Why do medical nebulizers differ in their output and particle size characteristics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Generation of aerosolized drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Drug delivery from jet nebulisers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

A comparison of commercial jet nebulizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Comparison of breath-enhanced to breath-actuated nebulizers for rate, consistency, and efficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Deposition patterns of aerosolized drugs within human lungs: effects of ventilatory parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Facemasks and facial deposition of aerosols.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Administration of aerosolized antibiotics in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Effect of sputum bacteriology on the quality of life of patients with bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Epidemiology and Outcomes of Ventilator-Associated Pneumonia in a Large US Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Endotracheally administered gentamicin for the prevention of infections of the respiratory tract in patients with tracheostomy: a double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Prevention of gram-negative bacillary pneumonia using polymyxin aerosol as prophylaxis. II. Effect on the incidence of pneumonia in seriously ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Aerosol Polymyxin and Pneumonia in Seriously Ill Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Aerosolized ceftazidime for prevention of ventilator-associated pneumonia and drug effects on the proinflammatory response in critically ill trauma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

The systemic inflammatory response in the development of ventilator-associated pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Cephalosporins and inflammatory host reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Fungal infections in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Invasive mycoses in organ transplant recipients: controversies in prophylaxis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Safety of aerosolized amphotericin B lipid complex in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Home nebulizer use among patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

The influence of age on aerosol deposition in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.1.71

21 January 2018

Identifiers

DOI

10.1517/17425247.3.1.71

1 reference

13 August 2017

1 reference